Experienced CEO within medical device technology to present at Oslo Medtech Summerparty
Strong marketing and sales focus shared by JenaValve™ Technology CEO Helmut J. Straubinger. Sales skills are essential, he claims. You are not the only one with the idea. Listen to advice, but stick to your idea, is his recommendation.
A stent, a prosthesis and a delivery system
Straubinger shared the exciting story of how JenaValve™ Technology has developed their TAVI system (trans arterial valve implant) – from the implementation of first in man studies, CE marking in several German centers, to the advanced system for marketing introduction of the product. Not only are system design and features pivotal to JenaValve, but equally important are the dexterity, skill and experience of the user, whether heart surgeon or cardiologist.
A safe product is essential
Straubinger advises young companies to start quality assurance very soon.
“To create a system that ensures precise placement, JenaValve has focused its product development on three fundamental, patented, design features: unique positioning feelers, the JenaClip™ and the low profile of the JenaValve prosthesis. These are the elemental differentiators with which the implantation can be accomplished more precisely and more easily than with other available TAVI systems”, Mr Straubinger expresses (
www.jenavalve.de).
Mininal intervention with the TAVI.
By using TAVI, the diseased aortic valve is replaced by a valve and not open surgery. Aortic stenosis, the most prevalent heart valve disease in Western countries, is increasing steadily with an aging population. The decision to surgically replace a diseased aortic valve is problematic in elderly patients due to associated high mortality and morbidity risks. In fact, elderly patients with severe aortic disease symptoms are not often considered candidates for surgery. JenaValve’s advanced TAVI systems are designed for this type of patient. The company’s TAVI systems are designed to reduce the long learning curve associated with TAVI devices now used by physicians.
President, CEO and member of the Board of Directors,
Helmut J. Straubinger (1958) has more than fifteen years experience in medical device technology including product development, manufacturing, sales and marketing, his main focus being peripheral stents, catheters and systems. He has held various positions in international companies with offices in Germany including CEO, OptiMed Medizinische Instrumente GmbH (manufacturing and international sales), CEO and CFO at the German subsidiary of C. R. Bard, Inc. and CFO at Nucletron Electronic AG. At his latest medtech position as CEO at OptiMed he set up an international sales and marketing organization, distributing interventional products in more than 40 countries, representing a sales volume of 15 million USD. He holds a Master of Business and Administration from the University of Applied Science, Munich, received in 1984.
